A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of Pumosetrag in Patients With Gastroesophageal Reflux Disease (GERD)

Edusa Pharmaceuticals, Inc.

Overview

The purpose of this study is to determine if pumosetrag is effective in treating Gastroesophageal Reflux Disease (GERD) symptoms in patients who have a history of GERD symptoms and are currently taking an acid suppression therapy, such as a Proton Pump Inhibitor (PPI).

Study Type

INTERVENTIONAL

Conditions

Gastroesophageal Reflux Disease

Interventions

PumosetragDRUG

PlaceboOTHER

PumosetragDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with history of Gastroesophageal Reflux Disease (GERD) symptoms (heartburn, regurgitation, acid taste in mouth). * Between ages of 18 - 70 inclusive. * Develop GERD symptoms following ingestion of a refluxogenic meal. * Able to take a stable Proton Pump Inhibitor (PPI) regimen for duration of study. * Understand and sign the informed consent form. Exclusion Criteria: * Pregnant or lactating women. * Allergic to pumosetrag or formulation excipients.

Locations (5)

Mayo Clinic Scottsdale

Scottsdale, Arizona, United States

Advanced Clinical Research Institute

Anaheim, California, United States

Mayo Clinic Jacksonville

Jacksonville, Florida, United States

Mayo Clinic Rochester

Rochester, Minnesota, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.